chronic hepatitis B raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
In Koch's postulates, he set out criteria to test if an organism is the cause of a disease, and these postulates are still used today. Both Koch and Pasteur played a role in improving antisepsis in medical treatment. In 1870–1885 the modern methods of bacteriology technique were introduced by the use of stains, and by the method of separating mixtures of organisms on plates of nutrient media. Though it had been known since the nineteenth century that bacteria are a cause of many diseases, no effective antibacterial treatments were available until the 20th century. In 1910, Paul Ehrlich developed the first antibiotic, by changing dyes that selectively stained Treponema pallidum—the spirochaete that causes syphilis—into compounds that selectively killed the pathogen. Ehrlich was awarded a 1908 Nobel Prize for his work on immunology, and pioneered the use of stains to detect and identify bacteria, with his work being the basis of the Gram stain and the Ziehl–Neelsen stain. In the early 20th century, there was debate about the classification of bacteria. In 1904, cyanobacteria were usually classified as a class of algae, which are eukaryotic. However, Haeckel at this time classed cyanobacteria with bacteria because they lacked nuclei. In 1938, Herbert Faulkner Copeland proposed that prokaryotes be granted their own kingdom. The development of the transmission electron microscope allowed better visualization of cell structure and helped to clarify issues.
On June 28, 2017, The Walt Disney Company, ABC's parent company, paid at least US$177 million to settle the lawsuit. Counsel for BPI stated that this was at that time the largest amount ever paid in a media defamation case in the United States. The product is regulated in different manners in various regions. In the US, the product is allowed to be used in ground beef, and it can be used in other meat products such as beef-based processed meats. The use of ammonium hydroxide as an anti-microbial agent is approved by the Food and Drug Administration, and is included on the FDA's list of GRAS (generally recognized as safe) procedures, and is used in similar applications for numerous other food products, including puddings and baked goods. The product is not allowed in Canada due to the presence of ammonia, and is banned for human consumption in the European Union. Some consumer advocacy groups have promoted the elimination of the product or for mandatory disclosure of additives in beef, while others have expressed concerns about plant closures that occurred after the product received significant news media coverage. In December 2018, pink slime was reclassified as "ground beef" by the Food Safety and Inspection Service of the United States Department of Agriculture.
== Contraindications == Use of zolpidem may impair driving skills with a resultant increased risk of road traffic accidents. This adverse effect is not unique to zolpidem but also occurs with other hypnotic drugs. Caution should be exercised by motor vehicle drivers. The U.S. Food and Drug Administration (FDA) recommends lower doses of zolpidem due to impaired function the day after taking it. Zolpidem should not be prescribed to older people, who are more sensitive to the effects of hypnotics including zolpidem, and are at an increased risk of falls and adverse cognitive effects, such as delirium and neurocognitive disorder. Animal studies have revealed evidence of incomplete ossification and increased intrauterine fetal death at doses greater than seven times the maximum recommended human dose or higher; however, teratogenicity was not observed at any dose level. There are no controlled data on human pregnancy. In one case report, zolpidem was found in cord blood at delivery. Zolpidem is recommended for use during pregnancy only when the benefits outweigh the risks.
Sources: en.wikipedia.org
== Adverse effects == Like other fluoroquinolones, difloxacin causes arthropathy in immature growing animals, particularly dogs. Otherwise, it is very well tolerated. The most common adverse effects are gastrointestinal effects such as vomiting, diarrhea and anorexia, even in overdose. Only supportive measures, and not additional treatment, are recommended for management of overdose or toxicity as the reactions are self-limiting. Contraindications include small and medium breeds of dogs that are less than 8 months old; large breeds less than 12 months old; giant breeds less than 18 months old; those with suspected CNS disorders; and hypersensitivity to difloxacin or any other fluoroquinolone.
==== Preterm or low-tone infants ==== Children who are born preterm (before 37 weeks), children born in the early term period (37 weeks–38 weeks and 6 days), and children born with low muscular tone, such as those with chromosomal abnormalities like Down syndrome or neurological conditions like cerebral palsy, may have difficulty in initiating breast feeds immediately after birth. These late preterm (34 weeks –36 weeks and 6 days) and early term (37 weeks–38 weeks and 6 days) infants are at increased risk for both breastfeeding cessation and complications of insufficient milk intake (e.g., dehydration, hypoglycemia, jaundice, and excessive weight loss). They are often expected to feed like term babies, but they have less strength and stamina to feed adequately. By convention, such children are often fed on expressed breast milk or other supplementary feeds through tubes, supplemental nursing systems, bottles, spoons, or cups until they develop a satisfactory ability to suck and swallow breast milk. Regardless of the feeding method chosen, human milk feedings, whether from the mother or a donor, are important in the brain development of premature infants, and the NICU having a standardized protocol for feeding is protective against dangerous gastrointestinal infections (necrotizing enterocolitis) in these infants. Frequent breastfeeding or small amounts of supplementation may be needed for successful outcomes; breast pumping or hand expression is often helpful in providing adequate stimulation to the mother's breasts.
GABAB receptor ligands. Agonists: baclofen, propofol, GHB, phenibut. Antagonists: phaclofen, saclofen. GABA reuptake inhibitors: deramciclane, hyperforin, tiagabine. GABA transaminase inhibitors: gabaculine, phenelzine, valproate, vigabatrin, lemon balm (Melissa officinalis). GABA analogues: pregabalin, gabapentin, picamilon, progabide 4-Amino-1-butanol is a biochemical precursor of GABA and can be converted into GABA by the actions of aldehyde reductase (ALR) and aldehyde dehydrogenase (ALDH) with γ-aminobutyraldehyde (GABAL) as a metabolic intermediate.
Sources: en.wikipedia.org
== Penalties == Following the CAS's guilty verdict on 12 January 2016, all affected players were formally named and began their suspensions immediately. The two-year ineligibility period was backdated to 31 March 2015, and credit was taken for provisional suspensions served during the 2014/15 offseason. This meant that most players were suspended until November 2016, and missed the entire 2016 season. Alwyn Davey and Leroy Jetta, who had served shorter provisional suspensions, were suspended until February 2017, which saw them miss the end of the 2015/16 NTFL season, the 2016 winter season and most of the 2016/17 NTFL season. Under the terms of the ban players were not permitted to:
Microgravity is the condition of low gravity found in outer space. Some of the major physiological implications that are associated with microgravity are bone loss, immunosuppression, enlargement of bones, muscle loss and movement of body fluids towards the head, spaceflight osteopenia, decrease in the function of cardiovascular system functions, decreased production of red blood cells, balance disorders, and also weaken the human immune system. In addition to this, fluid distribution is increased in the upper body due to the body's ability to pump blood faster to the upper body in microgravity conditions, known as the cephalad fluid shift. In addition, muscle regeneration protein levels have been estimated to vary due to microgravity conditions, including myostatin, activin A, and certain cytokines (e.g. IL-6, IL-10, IL-1ra), which are currently used as targets for drug delivery applications. The effects of microgravity has also investigated in wound healing processes, especially with the behavior of cell populations, such as fibroblasts. For cell studies, a Rotary Cell Culture System was used to mimic cell conditions in microgravity, where the bioreactor rotates horizontally, causing cell sedimentation in the vessel to be offset by the rotating fluid. This results in this light falling of cells, simulated in a microgravity environment. Studies showed a rearrangement of microtubules in cells due to microgravity, forming a dense, puzzled, network, unlike fibroblasts in a normal environment, which exhibit radial parallel formations.
Hydrogen–deuterium exchange mass spectrometry (HX-MS or HDX-MS) can determine the overall deuterium content of molecules which have undergone H/D exchange. Because of the sample preparation required, it is typically considered to provide an accurate measurement of non-exchangeable hydrogen atoms only. It can also involve H/D exchange in the gas phase or solution phase exchange prior to ionization. HDX-MS of proteins has several advantages when compared to HDX monitored using NMR spectroscopy: much less sample material is needed, the concentration of sample can be very low (as low as 0.1 uM), the size limit is much greater, and data can usually be collected and interpreted much more quickly. The deuterium nucleus is twice as heavy as the hydrogen nucleus because it contains a neutron as well as a proton. Thus a molecule that contains some deuterium will be heavier than one that contains all hydrogen. As a protein is increasingly deuterated, the molecular mass increases correspondingly. Detecting the change in the mass of a protein upon deuteration was made possible by modern protein mass spectrometry, first reported in 1991 by Katta and Chait. Determining site specific deuteration via mass spectrometry is more complicated than using NMR spectroscopy. For example, the location and relative amount of deuterium exchange along the peptide backbone can be determined roughly by subjecting the protein to proteolysis after the exchange reaction has been quenched. Individual peptides are then analyzed for overall deuteration of each peptide fragment.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.